The clinical pharmacology of ribavirin

Seminars in Liver Disease

Volumn 19, Issue 1 SUPPL. 1, 1999, Pages 17-24

  Glue, Paul ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Nucleoside analogue; Nucleoside transporter; Ribavirin

Indexed keywords

ANTACID AGENT; DACTINOMYCIN; MYLANTA; NUCLEOSIDE DERIVATIVE; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; STAVUDINE; ZIDOVUDINE;

CHEMICAL STRUCTURE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG UPTAKE; FIRST PASS EFFECT; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

ABSORPTION; ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTESTINE, SMALL; RIBAVIRIN;

EID: 0032949443     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Fernandez H, Banks G, Smith R. Ribavirin: a clinical overview. Eur J Epidemiol 1986;2:1-14
2. Patil SD, Glue P, Unadkat JD. Intestinal absorption of ribavirin is mediated by the Na+-nucleoside purine (N1) transporter. Pharm Res 1998;15:950-952
3. Ferrara EA, Oishi JS, Wannemacher RW Jr, Stephen EL. Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys. Antimicrob Agents Chemother 1981;19:1042-1049
4. Laskin OL, Longstreth JA, Hart CC, et al. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987;41:546-555
5. 14C-ribavirin distribution and pharmacokinetic studies in rats, baboons and man. In: Smith RA, Kirkpatrick W, (eds). Ribavirin: A Broad Spectrum Antiviral Agent. New York, NY: Academic Press; 1980:83-98
6. Data on file. Ribavirin. Kenilworth, NJ: Schering-Plough Corporation; 1998
7. Jarvis SM, Thorn JA, Glue P. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol 1998;123: 1587-1592
8. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1996; 1286:153-181
9. Connor E, Morrison S, Lane J, Oleske J, Sonke RL, Connor J. Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 1993;37:532-539
10. Lertora JJ, Rege AB, Lacour JT, et al. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1991;50:442-449
11. Zimmerman TP, Deeprose RD. Metabolism of 5-amino-1-beta-D-ribofuranosylimidazole-4-carboxamide and related five-membered heterocycles to 5′-triphosphates in human blood and L5178Y cells. Biochem Pharmacol 1978;27:709-716
12. Page T, Connor JD. The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochem 1990;22:379-383
13. Miller JP, Kigwana LJ, Streeter DG, Robins RK, Simon LN, Roboz J. The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann N Y Acad Sci 1977;284:211-229
14. Shulman NR. Assessment of hematological effects of ribavirin in humans. In: Smith RA, Knight V, Smith JAD, eds. Clinical Applications of Ribavirin. New York, NY: Academic Press; 1984:79-92
15. Paroni R, Del Puppo M, Borghi C, Sirtori CR, Galli Kienle M. Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers. Int J Clin Pharmacol Ther Toxicol 1989;27:302-307
16. Preston S, Drusano GL, Glue P, et al. Pharmacokinetics and absolute bioavailability of ribavirin using stable isotope methodology in normal volunteers. ICAAC Abstracts 1998
17. Khakoo S, Glue P, Grellier L, et al. Ribavirin and interferon alpha-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998;46:563-570
18. Willis RC, Carson DA, Seegmiller JE. Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci U S A 1978;75:3042-3044
19. Data on File. Ribavirin. Costa Mesa, Calif: ICN Pharmaceuticals, Inc.; 1997
20. Vogt MW, Hartshorn KL, Furman PA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376-1379
21. Hoggard PG, Barry MG, Khoo SH, Back DJ. Drug interactions with d4T phophorylalion in vitro. Br J Clin Pharmacol 1996; 42:278
22. Baba M, Pauwels R, Balzarini J, Herdewijn P, De Clercq E, Desmyter J. Ribavirin antagonized inhibitory effects of pyrimidine 2′, 3′-dideoxynucleosides but enhances inhibitory effects of purine 2′, 3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother 1987;31:1613-1617
23. Balzarini J, Herdewijn P, Clercq E. Potentiating effect of ribavirin on the anti-retrovirus activity of 3′-azido-2, 6-diaminopurine-2′, 3′-dideoxyriboside in vitro and in vivo. Antiviral Res 1989;11:161-171
24. Hartman NR, Ahluwalia GS, Cooney DA, et al. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Mol Pharmacol 1991;40:118-124
25. Malinoski F, Stollar V. Inhibitors of IMP dehydrogenase prevent sindbis virus replication and reduce GTP levels in Aedes albopictus cells. Virology 1981;110:281-289
26. Fraschini F, Scaglione F, Maierna G, et al. Ribavirin influence on theophylline plasma levels in adult and children. Int J Clin Pharmacol Ther Toxicol 1988;26:30-32
27. Japour AJ, Lertora JJ, Meehan PM, et al. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:235-246
28. Kramer TH, Gaar GG, Ray CG, Minnich L, Copeland JG, Connor JD. Hemodialysis clearance of intravenously administered ribavirin. Antimicrob Agents Chemother 1990;34:489-490